Skip to main content
Premium Trial:

Request an Annual Quote

GenInCode Files FDA 510(k) Submission For Polygenic Cardiovascular Disease Risk Test

NEW YORK – GenInCode announced Wednesday that it filed a 510(k) submission for its CARDIO inCode-Score (CIC-Score) in vitro polygenic risk score (PRS) test for cardiovascular disease with the US Food and Drug Administration.

The filing is part of the UK-based company's effort to expand the US commercial distribution of CIC-Score.

GenInCode currently offers the CIC-Score through the company's CLIA-certified and College of American Pathologists-accredited lab in Irvine, California, via an early access program.

The firm partnered with Milwaukee-based Eversana in 2021 to commercialize GenInCode's products within the US and last year filed its pre-submission for CIC-Score with the FDA.

The CIC-Score recently received a CPT PLA code (0401U) and the firm expects a payment rate for the test to be set by the US Centers for Medicare and Medicaid Services in October.

"Approval of the 510(k) kit/medical device filing will complement our US laboratory testing enabling GenInCode to accelerate commercial growth of CIC-Score in the US market," Matthew Walls, CEO of GenInCode, said in a statement. "Our early access program is seeing strong demand for use of our CIC-Score CLIA lab test to identify patients at high genetic risk, personalize treatment, and prevent [CVD]."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.